Trius: dump or double down on maker of MRSA antibiotic?
By Rex Graham The share price of Trius Therapeutics (TSRX) has rebounded from its 10 percent dip in the New Year that was triggered by its public offering of 7 million shares; however, uncertainty ab
Read More